Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

Disclosed is a use of Helminthostachys zeylanica, ugonins or compounds of formula (I) for the treatment or prevention of metabolic diseases comprising at least one selected from metabolic syndrome, excessive lipid accumulation, obesity, overweight, fatty liver, hepatic steatosis, hepatitis, cirrhosis, liver cancer, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia, hypercholesterolemia, cardiovascular disease, hyperglycemia, hyperinsulinemia, diabetes mellitus type 2, insulin resistance, insulin disorder, impaired glucose tolerance and a combination thereof.

An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C.sub.34H.sub.36N.sub.4O.sub.3), pheophorbide a methyl ester (C.sub.35H.sub.36N.sub.4O.sub.5), 1-linleoyl-3-linolenoyl-glycerol (C.sub.39H.sub.66O.sub.5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C.sub.53H.sub.98O.sub.6) and 1,3-dipalmitoyl-sn-glycerol (C.sub.35H.sub.68O.sub.5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

An extract of Asplenium nidus L. includes pyropheophorbide a methyl ester (C.sub.34H.sub.36N.sub.4O.sub.3), pheophorbide a methyl ester (C.sub.35H.sub.36N.sub.4O.sub.5), 1-linleoyl-3-linolenoyl-glycerol (C.sub.39H.sub.66O.sub.5), 1-linleoyl-2,3-dipalmitoyl-rac-glycerol (C.sub.53H.sub.98O.sub.6) and 1,3-dipalmitoyl-sn-glycerol (C.sub.35H.sub.68O.sub.5). The extract of Asplenium nidus L. is obtained by using a method including steps of: solvent extraction, using an solvent to extract an Asplenium nidus L. sample and to obtain an extract, with a w/v ratio between the solvent and the Asplenium nidus L. sample being 50˜60 mg/ml; and column chromatography, fractionating the extract with water and ethanol as eluent to obtain several fractions including fraction a to fraction i, and further evaporating and lyophilizing fraction b, c, d or their combination to obtain an extract of Asplenium nidus L.

A pharmaceutical composition for preventing and treating cancer of reproductive system and preparation method therefor. The pharmaceutical composition is prepared using one or more of the following as raw material: pinellia tuber, bighead atractylodes rhizome, gastralia tuber, liquorice root, Indian bread, white peony root, fresh ginger.

A pharmaceutical composition for preventing and treating cancer of reproductive system and preparation method therefor. The pharmaceutical composition is prepared using one or more of the following as raw material: pinellia tuber, bighead atractylodes rhizome, gastralia tuber, liquorice root, Indian bread, white peony root, fresh ginger.

The present invention discloses a C-glycosides composition from Pterocarpus marsupium comprising 5%-10% w/w Pterocarposide and Sabioside and a method for isolating the same. The composition further comprises of 30-60% w/w tannins. The invention also discloses a method of activating AMPK and inhibiting glucose production in mammalian cells using the aforementioned composition.

The present invention discloses a C-glycosides composition from Pterocarpus marsupium comprising 5%-10% w/w Pterocarposide and Sabioside and a method for isolating the same. The composition further comprises of 30-60% w/w tannins. The invention also discloses a method of activating AMPK and inhibiting glucose production in mammalian cells using the aforementioned composition.

The application discloses a traditional Chinese medicine composition for treating of type 2 diabetes, comprising the following raw materials: wild Descolor Cinquefoil Herb, wild Rhizoma imperatae, wild Root and Rhizome of Japanese Climbing Fern, Ginseng leaf (over 7 years), wild Rough Melic, wild Vitex negundo L., Morus alba L., green tea, wild auricularia, corn silk, dandelion root. The traditional Chinese medicine composition of the application is suitable for patients with type 2 diabetes and complications of type 2 diabetes, which has no adverse reactions and stable curative effect.

The application discloses a traditional Chinese medicine composition for treating of type 2 diabetes, comprising the following raw materials: wild Descolor Cinquefoil Herb, wild Rhizoma imperatae, wild Root and Rhizome of Japanese Climbing Fern, Ginseng leaf (over 7 years), wild Rough Melic, wild Vitex negundo L., Morus alba L., green tea, wild auricularia, corn silk, dandelion root. The traditional Chinese medicine composition of the application is suitable for patients with type 2 diabetes and complications of type 2 diabetes, which has no adverse reactions and stable curative effect.